Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zonisamide as adjunctive therapy for refractory partial seizures.

Martin J Brodie1

  • 1Epilepsy Unit, Western Infirmary, Glasgow, Scotland G11 6NT, UK. MartinJ.Brodie@clinmed.gla.ac.uk

Epilepsy Research
|December 1, 2005
PubMed
Summary

Zonisamide effectively treats refractory partial seizures in adults. Clinical trials show significant seizure reduction and good tolerability, supporting its use as an add-on therapy for epilepsy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do the third-generation antiseizure medications provide the "magic bullet" for drug-resistant epilepsy? Focus on cenobamate.

Epilepsia·2025
Same author

Interim analysis of the long-term efficacy and safety of azetukalner in an ongoing open-label extension study following a phase 2b clinical trial (X-TOLE) in adults with focal epilepsy.

Epilepsia open·2025
Same author

The impact of COVID-19 on people with epilepsy: Global results from the coronavirus and epilepsy study.

Epilepsia open·2024
Same author

Editorial: Epidemiology of epilepsy and seizures.

Frontiers in epidemiology·2024
Same author

Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial.

JAMA neurology·2023
Same author

Should substitution monotherapy or combination therapy be used after failure of the first antiseizure medication? Observations from a 30-year cohort study.

Epilepsia·2023

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Zonisamide is an antiepileptic drug with extensive global usage.
  • Over 2 million patient-years of experience support its efficacy in various epilepsy types.

Purpose of the Study:

  • To evaluate the efficacy and safety of zonisamide for refractory partial seizures in adults.
  • To analyze data from randomized, placebo-controlled trials.

Main Methods:

  • Four randomized, placebo-controlled trials involving 848 adult patients with refractory partial seizures.
  • Doses of zonisamide ranged from 100-600 mg/day, with comparisons to placebo.

Main Results:

  • Zonisamide doses ≥300 mg/day demonstrated significant efficacy in reducing complex partial, all partial, and all seizures compared to placebo.

Related Experiment Videos

  • A pivotal European study showed zonisamide 500 mg/day reduced complex partial seizure frequency by 51% versus 16% for placebo.
  • Supporting trials indicated dose-dependent benefits, with 20-27% of patients achieving ≥75% seizure reduction.

    • Conclusions:

    • Zonisamide is an efficacious and well-tolerated treatment option for adults with refractory partial seizures.
    • Pooled data confirm an excellent safety profile with mild-to-moderate adverse events.
    • Zonisamide can be used in combination with other antiepileptic drugs.